Eyenovia, Inc., an ophthalmic technology company, announced an amendment to its senior secured convertible debt due November 1, 2025, which delays monthly interest and amortization payments from ...

Eyenovia (EYEN) entered into an amendment to its outstanding senior secured convertible debt due November 1, 2025. The Amendment defers the Company’s monthly interest and amortization payments ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary ...

Eyenovia regains Nasdaq compliance, boosting investor confidence after a reverse stock split helped meet listing requirements. Shares surge 22.5%, driven by optimism around the company's ...

Eyenovia announces progress on its user-filled Optejet eye drop dispenser, aiming for U.S. regulatory approval in late 2025. Eyenovia, Inc. has made significant advancements in the development of ...

Rigorous testing has resulted in observations of the Optejet’s durable base unit performing over 30,000 sprays, and 98% of ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary ...

Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period in the prior year, the firm earned ($0.18) earnings per share.

NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...